Hypothesis: How do JAK2-inhibitors work
β
Ruben Mesa; Robert Peter Gale
π
Article
π
2009
π
Elsevier Science
π
English
β 205 KB
JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and ot